NCT01241240 - Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter

Enrollment

192

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

DRUG

bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)

One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.

DRUG

Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution

One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.

Trial Locations (2)

Bogotá

Mexico City